
Allergic to Your Smartwatch? You're Not Alone
Unusual and Severe Clinical Presentations
Since the early 2020s, contact allergies have been reported in connection with wearable electronics such as headsets, earbuds, and smartwatches. Several publications specifically reference allergic reactions were linked to Apple devices. While not extremely common, these reactions have occurred frequently enough that Apple has published dedicated guidance on its website.
According to Marcant, these allergies can present in unusual ways — for example, leukoderma linked to a nickel allergy from a smartwatch. More severe reactions have also been documented. One patient developed acute facial eczema with an angioedema-like appearance after wearing headphones. This led to an emergency department visit, where the patient was mistakenly treated with icatibant under the assumption of bradykinin-induced angioedema.
Common Offending Agents
From an allergology perspective, the main allergens include nickel, thiurams, and especially acrylates— commonly found in smartwatch components. Although Apple notes that the Apple Watch and its bands are designed so that acrylate- and methacrylate-containing components do not directly contact the skin, reactions have still been reported.
Additional cases involve Apple AirPods, with other unexpected allergens such as gold also implicated. In some instances, chemical analysis is required to confirm the presence of substances like octylisothiazolinone, as documented in recent headphone-related reactions.
Healthcare Professionals Also Affected
Contact allergies to connected devices are not limited to end users. A number of occupational cases have been reported, including among retail workers in Spain who handled adhesives while selling smartphone screen protectors. In those instances, the culprit was identified as 4-acryloylmorpholine.
Such devices are also widespread in healthcare environments, where patients may experience allergic reactions — most often due to acrylates. For example, skin reactions to electrodes used in transcutaneous electrical nerve stimulation therapy are well-documented.
'These findings suggest that legislation should mandate labeling of noncosmetic consumer products to enhance user safety and transparency,' Marcant concluded.
This story was translated from Medscape's French edition.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Schizophrenia Drugs Market Size, Share & Trends Analysis Report 2025-2030 - Innovative Therapies Lead the Schizophrenia Drugs Industry Amid Unmet Needs
Schizophrenia Drugs Market Dublin, July 07, 2025 (GLOBE NEWSWIRE) -- The "Schizophrenia Drugs Market Size, Share & Trends Analysis by Drug Class (Second- Generation Antipsychotics, Third-Generation Antipsychotics), Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030" report has been added to Schizophrenia Drugs Market was valued at USD 8.19 billion in 2024, and is projected to reach USD 11.20 billion by 2030, rising at a CAGR of 5.60%. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating Drugs Market Report Highlights The second-generation-antipsychotics held the largest market revenue share of 73.05% in 2024. The demand for second-generation antipsychotics in the schizophrenia drugs market is rising due to their improved safety and efficacy profiles compared to first-generation antipsychotics. The injectable antipsychotics treatment segment held the largest market revenue share in 2024. The demand for injectable antipsychotics is on the rise due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications. The hospital pharmacies segment held the largest market revenue share in 2024. Hospital pharmacies are well-positioned to provide comprehensive care, including managing complex medication regimens and monitoring side effects, which are critical for this condition. North America schizophrenia drugs market held the largest market revenue share of 38.65% in 2024. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders. This report addresses: Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segment and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listings for you to stay ahead of the curve Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes Report Attribute Details No. of Pages 100 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $8.19 Billion Forecasted Market Value (USD) by 2030 $11.2 Billion Compound Annual Growth Rate 5.6% Regions Covered Global Key Topics CoveredChapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.2.1. Drug Class and Route of Administration Outlook2.2.2. Distribution Channel Outlook2.2.3. Regional Outlook2.3. Competitive InsightsChapter 3. Schizophrenia Drugs Market Variables, Trends & Scope3.1. Market Lineage Outlook3.1.1. Parent Market Outlook3.1.2. Related/Ancillary Market Outlook3.2. Market Dynamics3.2.1. Market Driver Analysis3.2.2. Market Restraint Analysis3.3. Schizophrenia Drugs Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.1.1. Supplier Power3.3.1.2. Buyer Power3.3.1.3. Substitution Threat3.3.1.4. Threat of New Entrant3.3.1.5. Competitive Rivalry3.3.2. PESTEL Analysis3.3.2.1. Political Landscape3.3.2.2. Technological Landscape3.3.2.3. Economic Landscape3.3.3. Pricing Analysis3.3.4. Pipeline Analysis3.3.4.1. Phase 13.3.4.2. Phase 23.3.4.3. Phase 3Chapter 4. Schizophrenia Drugs Market: Drug Class Estimates & Trend Analysis4.1. Global Schizophrenia Drugs Market: Drug Class Dashboard4.2. Global Schizophrenia Drugs Market: Drug Class Movement Analysis4.3. Global Schizophrenia Drugs Market by Class, Revenue4.4. Second-Generation Antipsychotics4.5. Third-Generation Antipsychotics Chapter 5. Schizophrenia Drugs Market: Route of Administration Estimates & Trend Analysis5.1. Global Schizophrenia Drugs Market: Route of Administration Dashboard5.2. Global Schizophrenia Drugs Market: Route of Administration Movement Analysis5.3. Global Schizophrenia Drugs Market by Route of Administration , Revenue5.4. Oral Antipsychotics5.5. Injectable Antipsychotics Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis6.1. Global Schizophrenia Drugs Market: Distribution Channel Dashboard6.2. Global Schizophrenia Drugs Market: Distribution Channel Movement Analysis6.3. Global Schizophrenia Drugs Market by Distribution Channel, Revenue6.4. Hospital Pharmacies6.5. Retail Pharmacies6.6. Online Pharmacies6.7. Others Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Distribution Channel, and Route of Administration7.1. Regional Dashboard7.2. Market Size, & Forecasts Trend Analysis, 2018 to 20307.3. North America7.4. Europe7.5. Asia-Pacific7.6. Latin America7.7. MEA Chapter 8. Competitive Landscape8.1. Recent Developments & Impact Analysis, by Key Market Participants8.2. Company/Competition Categorization8.3. Vendor Landscape8.3.1. List of Key Distributors and Channel Partners8.3.2. Key Customers8.3.3. Key Company Market Share Analysis, 20248.3.4. Johnson & Johnson Services, Inc.8.3.5. Bristol-Myers Squibb Company/ Otsuka Holdings Co., Ltd.8.3.6. Sumitomo Pharma Co., Ltd.8.3.7. Eli Lilly and Company8.3.8. Alkermes8.3.9. VANDA PHARMACEUTICALS8.3.10. AstraZeneca8.3.11. AbbVie Inc.8.3.12. Pfizer Inc.8.3.13. H. Lundbeck A/S For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Schizophrenia Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio


Medscape
an hour ago
- Medscape
Copeptin as a Prognostic Marker in Emergency Hyponatremia
TOPLINE: Measuring copeptin levels in patients with hypotonic hyponatremia on emergency department (ED) admission provided key diagnostic insights. The copeptin to urinary sodium ratio more accurately predicted preserved extracellular fluid (ECF) than urinary sodium alone, and higher copeptin levels were linked to an increased risk for mortality. METHODOLOGY: Hypotonic hyponatremia is frequently observed during hospitalization and can increase the risk for mortality; in this context, copeptin, the C-terminal portion of the arginine vasopressin precursor, has emerged as a valuable marker for predicting complications associated with hypotonic hyponatremia. Researchers reported findings from a prospective cohort study conducted between June 2018 and August 2019 at a hospital in Italy, evaluating the accuracy of copeptin in identifying preserved ECF patterns and its predictive value in critically ill patients admitted to the ED. They included 84 adult patients (median age, 79 years; 47 women), in whom hyponatremia was confirmed by both direct and indirect ion-selective electrode assays after glucose correction; severe hyponatremia was observed in 34.5% of patients. Information on vital signs, ultrasound, medical history, and comorbidities was recorded, and pretreatment blood and urine samples were collected for laboratory analyses. ECF status was reassessed after discharge by three independent endocrinologists; in-hospital mortality and 6-month mortality were also evaluated. TAKEAWAY: Reduced ECF, increased ECF, and preserved ECF were reported in 28 patients each. A ratio of copeptin to urinary sodium of ≤ 29.5 pmol/mmol × 100 increased the likelihood of preserved ECF by more than fourfold (adjusted odds ratio, 4.28; P = .026), outperforming standard urinary sodium measurements (difference in area under the curve when the urinary sodium cut-off was > 30 mmol/L, 0.177; P = .013). Copeptin levels were positively associated with increased risks for in-hospital mortality (P < .0001) and 6-month mortality (P = .02), with levels above 13.6 pmol/L associated with a more than fourfold increased risk for 6-month mortality (hazard ratio, 4.507; P = .0001). Additional predictors of 6-month mortality included levels of N-terminal prohormone of brain natriuretic peptide (P = .031) and comorbidity burden (P = .009). IN PRACTICE: 'It is important to note that our results do not suggest replacing copeptin with other established clinical and biochemical evaluations routinely performed in emergency care, such as s-K [serum potassium] or NT-proBNP [N-terminal prohormone of brain natriuretic peptide] levels, when clinically appropriate. Rather, the aim of adjusting copeptin's predictive value for these common parameters in our analysis was to confirm its independent contribution,' the authors wrote. SOURCE: This study was led by Alessandro Maria Berton, Department of Medical Sciences, University of Turin, Turin, Italy. It was published online in The Journal of Clinical Endocrinology and Metabolism. LIMITATIONS: Patient recruitment was restricted to daytime hours and weekdays, thus limiting the generalizability. Certain analytes were not available for all patients during ED evaluation. Additional urinary parameters such as urine chloride, uric acid fractional excretion, and potassium levels were not compared with the copeptin/urinary sodium index. DISCLOSURES: This study received no specific grant from any funding agency. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
Eleva administers first dose of its Factor H biological treatment in C3-Glomerulopathy to healthy volunteers
First-in-human administration of CPV-104 marks a major step in drug development for the company's lead compound (Factor H) and in bringing a new medication to patients Freiburg im Breisgau, Germany, July 7, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, announced today the first dosing in its Phase 1 clinical study investigating the company's Factor H (CPV-104) program in C3-Glomerulopathy (C3G). In the first part of the clinical study, Eleva is investigating single-ascending doses of CPV-104 in healthy volunteers. 'Today's news marks our second proprietary program advancing into clinical trials, which is a great achievement from an organizational standpoint,' commented Björn Cochlovius, Ph.D., Chief Executive Officer of Eleva. 'Our Factor H biological therapy platform continues to evolve, gaining visibility among clinicians and potential partners alike. We will continue to add value to this program in C3G as our initial focus, dry AMD as a second indication, and potentially several others down the road, while creating the best infrastructure for its successful clinical development.' 'We are thrilled to advance our Factor H molecule into a first-in-human study to evaluate the safety and tolerability and pharmacokinetics for further clinical studies. I like to thank all team members at Eleva and our clinical partners for their continued efforts and commitment to meet this milestone,' commented Dr. Martin Bauer, Chief Medical Officer of Eleva. C3G represents a rare renal disease caused by the abnormal regulation of the complement system, particularly the alternative pathway of the complement cascade, a central part of the body's immune defense. Naturally occurring complement regulators such as Factor H offer a therapeutic approach to help restore balance within the complement system and have shown therapeutic potential in a range of indications. Preclinical data sets were recently published in Frontiers in Immunology and underscored Factor H (CPV-104)'s ability to act as a functional analogue of human Factor H, support normalization of serum C3 levels and lead to a rapid degradation of C3 deposits in the kidney. The program has received the Orphan Drug Designation in the European Union for C3G and is also being pursued by Eleva in dry AMD as a second indication. ABOUT ELEVAEleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biological therapeutics. Eleva's disruptive moss-based technology platform enables GMP-scale manufacturing of human proteins with tremendous therapeutic potential that other platforms cannot achieve. The company's proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. The lead program, Factor H (CPV-104), a recombinant human complement Factor H, has entered a Phase 1/2 clinical studies to treat C3 Glomerulopathy (C3G). An intravitreal formulation of the candidate is in late preclinical development to treat dry AMD. The company's aGal (RPV-001) program has completed a positive Phase 1b single-dose clinical trial to treat Fabry disease. MEDIA CONTACTS Fabienne ZeitterDirector Marketingpr@ +49 761 470 99 0 Valency CommunicationsMario Brkuljmbrkulj@ +49 160 9352 9951 INVESTOR CONTACT Cohesion BureauGiovanni Ca' +33 7 84 67 07 27 Attachment 250707_Eleva_1st_Dosing_FactorH_ENG